Complete Table of Contents 2017

Publication
Article

The table of contents for the latest issue of the journal ONCOLOGY: Perspectives on the Treatment of Hematologic and Solid Malignancies.

August 2017 Table of Contents

Volume 31 | Number 8
REVIEW ARTICLES

Changing Treatment Paradigms for Brain Metastases From Melanoma-Part 1: Diagnosis, Prognosis, Symptom Control, and Local Treatment Vyshak Alva Venur, Pauline Funchain, Rupesh Kotecha, et al

Circulating Tumor DNA as a Liquid Biopsy: Current Clinical Applications and Future DirectionsKimberly M. Komatsubara and Adrian G. Sacher

How an Expert Approaches It

Management of Castration-Resistant, Taxane-Resistant Prostate CancerTomasz M. Beer

Comorbidity Consult

Management of Sleep-Wake Disturbances Comorbid With CancerAnn M. Berger, Ellyn E. Matthews, and Ashley M. Kenkel

Point/Counterpoint

POINT: Should Radiation Therapy After Surgery for Ductal Carcinoma In Situ Be Standard Practice?Camille Berriochoa, Carisa Bohnak, Nicole Chahine, and Chirag Shah

COUNTERPOINT: Should Radiation Therapy After Surgery for Ductal Carcinoma In Situ Be Standard Practice?William C. Wood

Q&A

Fay Hlubocky on Recognizing and Addressing Clinician Burnout

Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content